Chromatide and Novasep have extended their partnership, which was initiated in December 2006, to develop large scale solid phase peptide and oligonucleotide synthesis technology
The aim of this continued partnership is to finalise co-development of a range of large scale peptide and oligonucleotide synthesis process, equipment and systems to meet the growing needs of biotechnology and pharmaceutical industries for more efficient, continuous flow instruments for gram to industrial scale production of high quality products.
The interest of this partnership is to combine Chromatide's considerable experience in solid phase synthesis, specifically in the fields of peptide and oligonucleotide synthesis, to Novasep' s expertise in synthesis services, chromatography, filtration and crystallisation technologies and processes in the biotechnology and pharmaceutical sectors to embrace pharmaceutical and biopharmaceutical industries' challenges in obtaining pure peptides and oligonucleotides and to provide them with efficient solutions.
Commenting on the announcement, Don Wellings, Chromatide's CSO, said: "We are delighted to be continuing to work with Novasep on this project.
"The extension of our collaboration is illustrative of the success we have achieved to date on developing the synthesis systems which Novasep aim to launch in 2008.
"The relationship is enabling us to combine our expertise in developing peptide and oligonucleotide synthesis technologies, which includes production of novel resins and instrumentation, with the skills and knowledge Novasep has to accelerate development of much needed new systems.
"Novasep is a world leader in the market with well established relationships within the biotechnology and pharmaceutical sectors which will enable users' rapid access to the technology we are co-developing".
